Leustatin

Cladribine, the active ingredient in Leustatin, is a purine nucleoside analog presented as an intravenous solution for intravenous use. It selectively targets malignant lymphocytes, providing therapeutic benefit in chronic lymphocytic leukemia and hairy cell leukemia in adult patients. The product conforms to EU market standards and is manufactured under strict quality controls.

GNH USA supplies Leustatin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Leustatin (cladribine) acts on malignant lymphoid cells and is employed in specific hematologic malignancies.

- Chronic lymphocytic leukemia: reduces malignant lymphocyte count and improves disease control. - Hairy cell leukemia: induces remission by eliminating abnormal B‑cells. - B‑cell chronic lymphoproliferative disorders: may be considered in specialist‑guided treatment regimens.

Cladribine can cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness during treatment. - Nausea: mild to moderate upset stomach. - Fever: transient elevations in body temperature. - Infections: increased susceptibility to bacterial infections. - Lymphopenia: reduced lymphocyte counts. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Severe infections: opportunistic infections requiring hospitalization. - Autoimmune hepatitis: liver inflammation of immune origin. - Severe neutropenia: critically low neutrophil counts. - Tumor lysis syndrome: rapid tumor cell breakdown. - Secondary malignancies: rare development of new cancers. - Life‑threatening allergic reactions: anaphylaxis in rare cases.

Cladribine therapy requires careful patient assessment and monitoring.

- Pregnancy: risk unknown; avoid unless benefits outweigh risks. - Renal impairment: evaluate kidney function before initiating therapy. - Hepatic impairment: monitor liver enzymes during treatment. - Active infections: screen and treat before starting cladribine. - Blood monitoring: perform regular complete blood counts. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine may interact with other medicines, necessitating vigilance.

Major Interactions (Avoid): - Live vaccines: contraindicated during and after treatment. - Concurrent immunosuppressive therapy: may increase infection risk. - Strong CYP450 inhibitors: may raise cladribine plasma levels.

Moderate Interactions (Monitor Closely): - Prophylactic antibiotics: adjust based on infection risk. - Antifungal agents: monitor liver function. - Non‑live vaccines: efficacy may be reduced. - Antiviral medications: observe for additive immunosuppression.